Mirum Pharmaceuticals Inc (NASDAQ: MIRM) will announce its second quarter 2026 financial results on August 5, 2026. The rare disease company will also host a conference call to discuss the quarterly figures and recent corporate progress. This update provides investors with timely insight into the company’s operational and financial trajectory for the period ending June 30, 2026.

The conference call is scheduled for Wednesday, August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT. Participants can join via dial-in or webcast.

An archived webcast of the event will be available for replay following the conclusion of the live broadcast.

Mirum Pharmaceuticals operates as a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. The company focuses on rare liver and rare genetic diseases, leveraging deep expertise and strong connections to patient communities. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX).

The company’s clinical-stage pipeline features several late-stage candidates. These include volixibat, an IBAT inhibitor for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC); brelovitug, a fully human monoclonal antibody for chronic hepatitis delta virus (HDV); zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP); and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum Pharmaceuticals, Inc. granted inducement awards to 6 new employees on July 10, 2026. The awards consist of non-qualified stock options to purchase 6,300 shares of common stock and 9,300 restricted stock units (RSUs). The Compensation Committee of Mirum’s Board of Directors approved the awards as an employment inducement under Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price of $122.13 per share, equal to the closing price of Mirum’s common stock on July 10, 2026. The options vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date. The remaining shares vest monthly over the following 36 months, subject to continued service.

The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable initial vesting date. Vesting for both awards is contingent upon the new employees maintaining their service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms of Mirum’s 2020 Inducement Plan and individual award agreements.

Award Details

Mirum Pharmaceuticals focuses on rare liver and rare genetic diseases. Its commercial portfolio includes LIVMARLI, CHOLBAM, and CTEXLI. The company’s clinical-stage pipeline features volixibat, brelovitug, zilurgisertib, and MRM-3379.